文献速递神经介入DSA

医生如何对待适合静脉阿替普酶和血管内治疗的急性缺血性卒中患者的静脉阿替普酶治疗?UNMASK-EVT的见解

How Do Physicians Approach Intravenous Alteplase Treatment in Patients with Acute Ischemic Stroke Who Are Eligible for Intravenous Alteplase and Endovascular Therapy? Insights from UNMASK-EVT.
PubMed 文献 · AJNR Am J Neuroradiol · 2020-01-23

这项国际多学科调查纳入607名参与急性卒中治疗的医生,随机分配22个病例场景中的10个,其中14个有指南推荐的阿替普酶指征。在有指南推荐阿替普酶的病例中,医生在当前本地资源下赞成阿替普酶的比例为82.0%,在假设理想条件下为79.3%(P < .001)。在假设理想条件下,神经介入放射科医生最常避免静脉阿替普酶(6.28%,OR = 2.40;95% CI,1.01-5.71)。

要点

  • 有指南推荐阿替普酶的病例中,当前本地资源下82.0%的决策赞成阿替普酶,假设理想条件下为79.3%(P < .001)。
  • 假设理想条件下,神经介入放射科医生最常避免静脉阿替普酶(6.28%,OR = 2.40;95% CI,1.01-5.71)。
  • 当前与理想决策不同时,多数医生希望在理想环境中在静脉阿替普酶基础上增加血管内治疗(196/3861条回答,5.1%)。

核心结论

  • 在适合血管内治疗和静脉阿替普酶的急性缺血性卒中患者中,假设理想条件下赞成静脉阿替普酶的决策率略低于当前本地资源下的决策率。

研究设计与样本

  • 国际多学科调查,607名参与急性卒中治疗的医生随机分配22个病例场景中的10个,其中14个有指南推荐的阿替普酶指征(9个为1A级推荐,5个为2B级推荐)。
  • 医生被问及在当前本地资源和假设理想条件下如何治疗患者,回答选项包括抗凝/抗血小板治疗、血管内治疗、血管内治疗联合静脉阿替普酶、静脉阿替普酶。
  • 计算决策率并进行多变量回归分析,以确定与放弃静脉阿替普酶决策相关的变量。

诊断标准与关键数值

  • 在有指南推荐阿替普酶的病例中,医生在当前本地资源下赞成阿替普酶的比例为82.0%,在假设理想条件下为79.3%(P < .001)。
  • 假设理想条件下,神经介入放射科医生最常避免静脉阿替普酶(6.28%,OR = 2.40;95% CI,1.01-5.71)。
  • 当前与理想决策不同时,多数医生希望在理想环境中在静脉阿替普酶基础上增加血管内治疗(196/3861条回答,5.1%)。

临床应用与阅片要点

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

BACKGROUND AND PURPOSE: With increasing use of endovascular therapy, physicians' attitudes toward intravenous alteplase in endovascular therapy-eligible patients may be changing. We explored current intravenous alteplase treatment practices of physicians in endovascular therapy- and alteplase-eligible patients with acute stroke using prespecified case scenarios and compared how their current local treatment practices differ compared with an assumed ideal environment.

MATERIALS AND METHODS: In an international multidisciplinary survey, 607 physicians involved in acute stroke care were randomly assigned 10 of 22 case scenarios, among them 14 with guideline-based alteplase recommendations (9 with level 1A and 5 with level 2B recommendation) and were asked how they would treat the patient: A) under their current local resources, and B) under assumed ideal conditions. Answer options were the following: 1) anticoagulation/antiplatelet therapy, 2) endovascular therapy, 3) endovascular therapy plus intravenous alteplase, and 4) intravenous alteplase. Decision rates were calculated, and multivariable regression analysis was performed to determine variables associated with the decision to abandon intravenous alteplase.

RESULTS: In cases with guideline recommendations for alteplase, physicians favored alteplase in 82.0% under current local resources and in 79.3% under assumed ideal conditions (P < .001). Under assumed ideal conditions, interventional neuroradiologists would refrain from intravenous alteplase most often (6.28%, OR = 2.40; 95% CI, 1.01-5.71). When physicians' current and ideal decisions differed, most would like to add endovascular therapy to intravenous alteplase in an ideal setting (196/3861 responses, 5.1%).

CONCLUSIONS: In patients eligible for endovascular therapy and intravenous alteplase, we observed a slightly lower decision rate in favor of intravenous alteplase under assumed ideal conditions compared with the decision rate under current local resources.

来源:AJNR Am J Neuroradiol,查看原文。版权归原作者所有。

引用

  1. Ospel JM, Kashani N, Fischer U, et al. How Do Physicians Approach Intravenous Alteplase Treatment in Patients with Acute Ischemic Stroke Who Are Eligible for Intravenous Alteplase and Endovascular Therapy? Insights from UNMASK-EVT. AJNR Am J Neuroradiol. 2020. PMID: 31974081. doi:10.3174/ajnr.A6396

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。